How the NMPA is Changing
the Chinese Pharmaceutical Industry

China is currently recognized as the world second largest pharmaceutical market. However, the regulatory policies have been very challenging for many large foreign pharmaceutical enterprises, as well as innovative local companies. Some of the reasons for those challenges are:

  • Complicated and long review processes compared to most major countries.
  • Limited clinical trial quality checks with no enforcement mechanism, which caused issues when compared with international standards.
  • Lack of people in regulatory bodies which caused a 20000+ backlog and long queue time for approval.

    Free download

    Please fill in the form in order to get this document in your email inbox. We value your privacy and will never share your data with third parties.

    Use a valid email address
    Optional

    Other publications by CSOFT

    Got questions?

    Speak to one of our support agents.